CHEK2 and breast cancer: We compared our findings to breast (n = 3) and non-breast cancers (n = 25) from individuals heterozygous for CHEK2 gPVs and to breast (n = 7) and non-breast cancers (n = 21) from individuals heterozygous for BRCA1/2 gPVs (13).